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 Summary
 Background: Prostate cancer (PC) is an important medical and socio-economical problem due to its increasing 
incidence. The development of the prostate specific antigen (PSA) test, and a continuing decrease 
in the rates of other common neoplasms, such as lung and stomach since mid-1980s, prostate 
cancer has become one of the most common cancers among men. Prostate cancer (PC) is the second 
most common cancer in men, preceded only by lung cancer, and its early diagnosis is crucial for a 
successful treatment, that will prolong survival and improve quality of life.
  The main objective of our study was to evaluate the role of magnetic resonance imaging (MRI), 
magnetic resonance spectroscopy (MRS) and transrectal ultrasound (TRUS) in detecting prostatic 
pathologies and staging of prostate cancer by correlating these methods with histopathological results.
 Material/Methods: The study is a cross-sectional diagnostic study performed in 66 patients with a high degree of 
clinical suspicion of prostatic pathology. All patients underwent TRUS, T1W, T2W, DWI, and 
3D PRESSMRS sequences, and we also calculated ADC values and Cho Cr/Cit MRS ratios for all 
patients.
 Results: Combination of MRI and MRS showed the highest diagnostic accuracy among the imaging modalities 
in detecting of prostatic neoplasm, followed by MRI, and then by TRUS. MRS plays a complementary 
role to MRI, by increasing its diagnostic accuracy. Due to a high cost, limited availability and 
increased scanning time, combination of MRI and MRS is currently not recommended as a first line 
investigation for detecting prostate neoplasms, hence USG (TRUS) remains the first line investigation 
due to its low cost, easy availability, time effectiveness and comparable efficacy.
 Conclusions: MRI MRS has more diagnostic accuracy than MRI alone for detection of prostate pathologies. MRS, 
plays significant complementary role and should be included in the routine MR imaging protocols. 
MRI helps in diagnosis, localization, better tissue characterization and staging of prostate cancer. 
TRUS is easily available, cost effective and has comparable efficacy.
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Background
Prostate cancer (PC) is the second most common cancer and 
the sixth leading cause of cancer related death among men 
worldwide. Moreover incidence of prostate cancer has been 
increasing over the years [1].
Prostate cancer is a potentially curable disease and com-
bined effects of early detection and therapeutic interven-
tion are likely causes of the observed reduction in prostate 
cancer mortality. The main goal of prostate cancer imag-
ing is early diagnosis and more accurate disease character-
ization owing to the combined effects of anatomic, func-
tional and molecular assessments [2,3]. PSA, digital rectal 
examination(DRE), TRUS-guided biopsy and computed 
tomography (CT) cannot correctly localize, stage or deter-
mine the volume, and aggressiveness of prostate cancer, 
however MRI can be used for al those reasons [4,5].
Material and Methods
We performed a cross-sectional study to evaluate the 
efficacy of TRUS, MRI, MRI+MRS in various prostatic 
pathologies, with the main focus on detecting prostate 
cancer. A total of 66 patients were informed about the 
nature, and objective of the study and written informed 
consent was taken following an approval of an institu-
tional ethics. All patients with a strong clinical suspicion 
of prostate pathologies (lower urinary tract symptoms like 
increased frequency of micturition, hesitancy, urgency 
and hard/enlarged prostate on digital rectal examination), 
enlarged prostate on ultrasound of the abdomen or raised 
PSA levels (>4 ng/ml) were included in the study.
Patients unwilling or unable (claustrophobic) to undergo 
MRI/MRS, with metallic hip implants or any other metallic 
implants or devices that might distort local magnetic fields 
and compromise the quality of MRI/MRS together with 
patients who underwent a recent prostatic biopsy were 
excluded from the study.
All patients underwent TRUS and later MRI with T1WI, 
T2WI, DWI and 3D PRESSMRS sequences; ADC values and 
Cho Cr/Cit ratios were calculated.
Machines Used – Ultrasonography (USG) machine – Mylab 
50 and my lab 40, Corevision.
MRI – 1.5 Tesla (GE health care).
Statistical methods
The demographic data were obtained and summarized as 
absolute numbers and percentages. Patients were grouped 
according to the zonal distribution of lesions on USG and 
MRI, characterization of lesions on USG and MRI and his-
topathological interpretation of lesions. Histopathological 
results were compared with USG and MRI. Descriptive 
statistics like mean and standard deviation were obtained. 
The means across different assessment modalities were 
compared using one-way analysis of variance (ANOVA). 
The mean apparent diffusion coefficient (ADC) value was 
obtained. The mean ADC across grades of lesions based on 
Gleason score as well as prostatic lesions were compared 
using one-way ANOVA. The diagnostic accuracy of USG 
and MRI was obtained in comparison with histopatho-
logical findings. Receiver operating characteristics (ROC) 
analysis was performed for PSA and mean Cho Cr/Cit value 
with reference to histopathological findings to determine 
respective cut-off values. The diagnostic accuracy of such 
obtained cut-off values was also determined. Furthermore, 
the diagnostic accuracy of USG and MRI in predicting 
malignancy was determined. Also, the agreement of MRI 
with final of malignancy was assessed.
All the analyses were performed using SPSS version 20.0 
(IBM Inc.)
Results
The largest proportion of patients in our study belonged to 
the age group 60-69 years constituting about 45.4% of all 
subjects.
The mean age in the benign category was 60.68 years, SD 
of 8.69 years, while the mean age in the malignant category 
was 68.97 years, SD of 7.97 years.
On MRI, the majority of lesions 45 (68.2%) were hypoin-
tense on T2W sequences, while 21(31.8%) had a heteroge-
neous signal intensity on T2W images.
When MRS was combined with MRI, 24 patients (36.36%) 
had a benign pathology and 42 patients (63.64%) had a 
malignant pathology. Out of 42 malignant lesions, 21 lesions 
were peripheral zone neoplasms while 14 lesions were tran-
sitional zone neoplasms on MRI+MRS (Tables 1–4). The 
mean Cho Cr/Cit MRS values of benign, inflammatory and 
neoplastic lesions were significantly different (Table 1).
On histopathology, the majority of lesions (62.12%) were 
diagnosed as malignant lesions. 6 patients (9.09%) were 
diagnosed with chronic prostatitis, and 19 patients (28.78%) 
were diagnosed with benign prostatic hyperplasia (Figure 1) 
Out of 41 patients with malignancies on histopathology, the 
majority had peripheral zone lesions.
The mean age of patients with malignant neoplastic dis-
ease (68.97±7.97 years) was significantly higher than that 
of patients with benign disease (60.68±8.69 years).
Out of 41 patients with a malignant pathology on histopa-
thology, 32 were correctly identified as malignant on USG, 
39 were correctly identified on MRI and 40 were correctly 
identified when MRS was added to MRI.
An inverse correlation was observed between Gleason 
scores and ADC values in pathologically proven neoplasms 
i.e. the lower the ADC value, the higher the tumor grade.
Thus, a combination of MRI+MRS (final diagnosis) showed 
the highest diagnostic accuracy among the imaging modali-
ties for detection of prostatic neoplasms, followed by MRI 
and then by TRUS. MRS plays a complementary role to 
MRI, by increasing its diagnostic accuracy detecting pros-
tate neoplasms (Tables 4, 5).
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On DCE MRI, areas demonstrating early, rapid and intense 
contrast uptake with subsequent plateau or wash-out 
phase were considered suspicious for the presence of 
malignancy. Some patients underwent DCE-MRI.
In our study, malignant cases showed an early wash-out 
and they were all malignant. Out of 4 cases that did not 
show a rapid wash-out, none turned out as malignant.
Discussion
Prostate cancer screening
Men who aged 50–60 years or older who present with 
lower urinary tract symptoms are now offered serum 
prostate-specific antigen (PSA) testing. The diagnostic 
Histopathology
MRS [Mean ±SD (n)]
Benign prostatic hyperplasia Carcinoma Prostatitis
Mean Cho Cr/Cit value 0.50±0.25 (19) 1.89±1.21 (41) 0.93±0.57 (6)
Table 1. Mean Cho Cr/Cit values as per histopathological diagnosis.
P-value <0.0001 using one-way ANOVA.
Final diagnosis
Histopathology findings
P-value*
Non-carcinoma (n=25) Carcinoma (n=41)
Non-malignant 23 1
<0.0001
Malignant 2 40
Sensitivity 97.56%
Specificity 92.00%
Positive predictive value 95.24%
Negative predictive value 95.83%
Table 2. Comparison of final diagnosis (MRI+MRS) with histopathology.
* Obtained using the chi-square test.
Histopathology
DW
P-value*
Non-carcinoma Carcinoma
Benign 17 8
<0.0001(HS)
Malignant 2 39
Sensitivity 82.98%
Specificity 89.47%
Positive predictive value 95.12%
Negative predictive value 68.00%
Table 3. Comparison of diffusion weighted imaging of MRI and histopathology finding in predicting malignancy.
* Obtained using Chi-Square test; HS – highly significant.
Diagnostic parameter USG MRI Final diagnosis (MRI+MRS)
Sensitivity 32/41 78.05% 39/41 95.12% 40/41 97.56%
Specificity 22/25 88.00% 21/25 84.00% 23/25 92.00%
Positive predictive value 32/35 91.43% 39/43 90.70% 40/42 95.24%
Negative predictive value 22/31 70.97% 21/23 91.30% 23/24 95.83%
Table 4. Comparison of diagnostic accuracy of different imaging modalities.
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evaluation is further offered by transabdominal or tran-
srectal ultrasound.
Serum PSA for prostate cancer screening and its impact
PSA-based screening significantly increases the frequency 
of prostate cancer diagnosis at an early stage, which is 
important for further treatment. It is predicted that PSA-
based screening can help to reduce the mortality by 20%, 
but at a high cost of over diagnosis and overtreatment.
Transrectal USG (TRUS) (Figure 2)
It is a widely available, low-cost diagnostic tool used for 
morphological assessment of the prostate gland and its 
pathologies. However, it can neither reliably diagnose an 
intra-prostatic cancer nor detect its extra capsular exten-
sion in contrast to MRI (Figures 3, 4). Although most can-
cers in the peripheral zone (PZ) are hypoechoic, some are 
hyperechoic. Others, including central gland cancers, are 
often difficult to diagnose. Color and power doppler imag-
ing can further add information about the vascularity (and 
neovascularization) of the prostate and its lesions, however 
it is not 100%reliable. Therefore ultrasound can be used 
only for initial screening of prostate cancer. In case with 
equivocal findings, further tissue characterization is done 
by MRI. Currently ultrasound is used for initial screen-
ing and to guide prostatic biopsies. Most of the lesion can 
be diagnosed using transabdominal or transrectal ultra-
sound. If needed, further MRI with spectroscopy and 
contrast administration is done to obtain more accurate 
information. Some lesions may have been missed in our 
study due to a relatively low sensitivity of TRUS in detect-
ing malignancy. Similar findings were also found by Sheth 
S et al. who concluded that clinical stage A carcinomas may 
be difficult to detect on US, and findings are often nonspe-
cific. Any suspicious peripheral zone lesions should under-
go MRI or TRUS-guided biopsy before being diagnosed as 
malignant or benign [6].
In our study, on USG, the majority of patients (51.5%) were 
diagnosed with malignant pathologies (34), while the rest 
had benign pathologies i.e. benign prostatic hyperplasia (26, 
39.4%) and prostatitis (6, 9.09%). Out of 25 patients with 
benign pathology on follow up, 22 were correctly diagnosed 
as a benign on USG follow-up. The sensitivity of USG was 
78.05%, specificity was 88.00%, PPV was 91.43% and NPV 
was 70.97%.
TRUS-Guided Systematic Biopsy
It has advantages, as it is real-time and easy of use. Often it 
is combined with MRI (TRUS-MRI fusion) for better locali-
zation, guidance, approach and morphological assessment 
of the lesion.
Staging of prostate cancer – Gleason’s score
Definitive diagnosis is established only by transrectal 
ultrasound-guided biopsy (TRUS biopsy) and histopatho-
logical analysis for determination of cancer grade (Gleason 
score) and volume. The prognosis and choice of therapy is 
dependent on this information.
A significant relationship exists between tumor aggressive-
ness as denoted by Gleason score and the Cho+Cr/Cit ratio. 
In our study, an inverse correlation was observed between 
Gleason scores and ADC values in pathologically proven 
cases of neoplasms i.e. the lower the ADC value, the higher 
is the tumor grade.
Magnetic resonance imaging (Figures 3, 5–7)
Magnetic resonance imaging (MRI) is an imaging modality 
which significant information on the anatomy, pathology 
and extent of prostate pathologies. MRI has many advantag-
es that make it a favorable modality (e.g., high contrast reso-
lution, ability to obtain images in any plane i.e. multiplanar 
imaging, no ionizing radiation, and safety of using particu-
late contrast media rather than those containing iodine).
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Figure 1.  Bar diagram showing number of patients as per 
histopathological diagnosis of lesions.
Diagnostic parameter
P-value*
USG vs. MRI USG vs. final diagnosis (MRI+MRS) MRI vs. final diagnosis (MRI+MRS)
Sensitivity 0.052 0.018 (S) 0.999
Specificity 0.999 0.999 0.663
Positive predictive value 0.999 0.833 0.694
Negative predictive value 0.135 0.043 (S) 0.969
Table 5. Statistical significance testing of various diagnostic parameters between imaging modalities.
* Obtained using the z-test for proportions.
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In our study, lesions were identified and diagnosed using 
TRUS, T1W, T2W, DWI and 3D PRESSMRS sequences. 
Then, the lesions were characterized based on their appear-
ance and the Cho+Cr/Cit ratio of these lesions was calcu-
lated from the corresponding metabolite peaks. Lesions 
were localized to a particular zone.
Diffusion-weighted imaging
DWI exploits the property of constant Brownian motion 
of water molecules in tissues. This property is affected 
by increased cellularity, tissue organization, extracellu-
lar space, and integrity of cell membranes. Prostate can-
cer foci are composed of tightly packed cellular elements 
with reduced extracellular space, which can be visual-
ized on DWI images as areas of restricted diffusion (high 
signal intensity), with corresponding low signal intensity 
on apparent diffusion coefficient (ADC) maps. Diffusion-
weighted imaging demonstrates restriction of diffusion and 
reduction of apparent diffusion coefficient values in neo-
plastic tissue. This technique requires short acquisition 
time and provides high contrast resolution between neo-
plastic and normal tissues.
Magnetic resonance spectroscopy
Magnetic resonance spectroscopy, is an adjuvant to mag-
netic resonance imaging, which offers a level of tissue 
characterization that can match histological and biochemi-
cal diagnosis. MR spectroscopy is also known as chemical 
shift imaging.
One such application is in the field of prostate neoplasm. 
MRS when combined with MRI has a potential to detect, 
Figure 2.  Ultrasonography and TRUS in a 85 year male with giant prostatomegaly (A) transabdominal USG showing prostate of volume 433 cc 
(B) TRUS showing enlarged right lobe of prostate (C) TRUS showing enlarged prostate.
A
B C
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Figure 3.  Ca prostate with extracapsular extension and involvement of seminal vesicle. 1. T2W axial image showing (1A) hypointense signal in 
the root of right seminal vesicle(arrow) (1B) diffuse hypointense signal in both TZ and PZ with ECE. 2. DCE- MRI showing early arterial 
enhancement. 3. (A) Area of restricted diffusion on DWI with (B) corresponding hypointensity on ADC map. 4. MRS showing raised choline 
and decrease citrate peak.
1A
3A
1B
3B 4
2
Figure 4.  BPH. 1. T2W images (1A) axial, (1B) sagittal and (1C) coronal showing heterogeneous signal in central gland with multiple well 
circumscribed nodules. 2. (2A)DWI and (2B) ADC map do not show restricted diffusion mean ADC value is 1023×10–6 mm2/s. 
3. MR spectroscopy: Cho+ Cr/ Ci ratio is normal 
1A 1B 1C
2B 2A 3
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characterize and localize lesions, and it can differentiate 
between benign and malignant lesions and determine the 
stage and aggressiveness of prostate neoplasms. In addi-
tion, it can also predict the prognosis and help in manage-
ment of prostate lesions. It thus plays a complementary 
role to MRI in patients with prostate neoplasms. MR spec-
troscopy, which depicts a higher ratio of choline and cre-
atine to citrate in neoplastic tissue than in normal tissue, 
is generally accepted. The technique also allows detection 
of prostate neoplasms in the transitional zone. However, 
it requires a long acquisition time, does not directly 
depict the periprostatic area, and is frequently affected by 
artifacts.
Lesions were detected and localized on MRS by assessing 
the maximum Cho+Cr/Cit ratio. The maximum Cho+Cr/Cit 
ratio was also used by Kobus et al. [7].
MRI and MRS localized lesions to respective zones with 
equal efficacy. However, MRS played a complementary role 
to MRI in localization of lesions within zones. A study by 
Scheidler et al. [8] showed that the combined use of MR 
imaging and MR spectroscopy improves the detection of 
tumors within the peripheral zone.
Figure 5.  Peripheral Zone Carcinoma. (A) T2W axial image showing focal circumscribed area of moderate hypointensity (arrow) in right peripheral 
zone. (B) Corresponding area showing restricted diffusion on DWI and hypointensity on ADC map. (C) Early arterial enhancement on 
DCE noted in the corresponding area(arrow). (D) MRS shows elevated choline peak and reduced citrate peak with voxel placement in the 
suspicious area.
A
C D
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In our study, patients diagnosed with benign prostatic 
hyperplasia on histopathology had a mean Cho+Cr/Cit value 
of 0.50±0.25 (19 patients). Patients with a malignant pathol-
ogy had a mean Cho+Cr/Cit value of 1.89±1.21 (41 patients) 
and in patients with prostatitis it was 093±0.57 (6 patients). 
These findings were in line with previous studies by 
Kurhanewicz et al. [9] (mean Cho+Cr/Cit ratio in malignancy 
of 2.1±1.3 and in BPH of 0.61±0.21) and Kim JK et al. [10] 
(mean Cho+Cr/Cit in malignancy of 1.89±1.21 (41 patients) 
and in BPH of 0.50±0.25 (19 patients). The mean value of 
Cho+Cr/Cit for malignant lesions in our study was signifi-
cantly higher than that for benign lesions, which is in line 
with studies by Shukla-Dave A et al. [11], Kurhanewicz 
et al. [9], Kim JK et al. [10] and Kurhanewicz et al. [12].
Kobus et al. [7] found a significant correlation between 
aggressiveness and maximum Cho+Cr/Cit ratios and they 
stated that MRS offered a potential for a noninvasive in 
vivo assessment of prostate neoplasm aggressiveness. 
Similarly, Zakian et al. [13] observed that Cho+Cr/Cit ratios 
of prostate tumors and tumor volume correlated with 
Gleason scores, and that there was a trend toward increas-
ing Cho+Cr/Cit ratios with increasing Gleason scores in 
lesions identified correctly with MRS.
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In our study, out of 41 patients with a malignant pathol-
ogy on histopathology, 40 were correctly diagnosed by 
MRI+MRS in comparison to 39 on MRI and 32 on USG. 
However, similarly to other modalities, the combination 
of MRI+MRS identified 23 out of 25 benign cases. Thus, 
the combination of MRI+MRS correctly identified 2 addi-
tional cases of malignancy in comparison to MRI alone and 
8 additional cases of malignancy in comparison to USG 
alone, reflecting that it had the highest sensitivity (97.56%) 
and specificity (92%) among all the imaging modalities in 
our study. Out of 2 cases that were wrongly diagnosed as 
malignant on MRI+MRS, 2 cases were diagnosed as BPH 
on histopathology. PPV and NPV was 95.24% and 95.83%, 
respectively, when MRS was added to MRI. Scheidler et 
al. [8] found sensitivity and specificity for neoplasm detec-
tion of 91% and 95%, respectively for a combined use of MR 
spectroscopy and MR imaging, in comparison to 77% sen-
sitivity of MRI alone. Thus, they observed that addition of 
3D MRS to MRI provided a better detection of prostate neo-
plasms with sensitivity and specificity higher than in the 
case of MRI alone. Squillaci et al. [14] observed that sensi-
tivity of neoplasm detection was increased on MRS (89%) in 
comparison to MRI (85%), while specificity of either modal-
ity remained the same
Dynamic contrast-enhanced MRI
The basic principle of DCE-MRI is related to tumor angio-
genesis. Any tumor >2 mm inevitably shows angiogenesis. 
Prostate cancer, due to the expression of vascular endothe-
lial growth factor (VEGF), is no exception. There is a dif-
ference between the interstitial space of cancerous tissue 
and normal tissue. Due to large interstitial spaces in the 
cancerous tissue, there is a difference in the concentra-
tion of intravenous contrast material between intravascu-
lar and extravascular spaces, which accentuates contrast 
transfer through vascular walls and thus results in unique 
enhancement patterns of strong early enhancement and 
rapid washout of contrast. DCE-MRI has a high accuracy 
and sensitivity. On DCE MRI, areas demonstrating early, 
rapid, and intense contrast uptake with subsequent plateau 
or wash-out phase were considered suspicious for the pres-
ence of malignancy.
Multi-parametric or combined approach of different MRI sequences 
to reach final diagnosis
In our study, we aimed to determine the role of 1.5T mag-
netic resonance imaging and transrectal ultrasound in the 
evaluation of prostatic pathologies and in the detection 
and staging of prostate neoplasm. We have correlated our 
Figure 6.  Transition zone Carcinoma. (A) T2W axial image showing ill-defined hypointensity involving predominantly left transition zone with 
extracapsular extension (arrow). (B) DCE shows early arterial enhancement in the corresponding area. (C) Focal area of restricted diffusion 
and ADC hypointensity in the corresponding area. (D) Loss of normal T2W hyperintense signal in left seminal vesicle (above) with post 
contrast enhancement(below). (E) MRS shows elevated choline and reduced citrate peak.
A B C
D E
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findings with biopsy and post-operative histopathological 
diagnosis.
Abscesses also show restriction of diffusion just like most 
prostate cancers. However, they appear hyperintense on 
T2WI and show only peripheral enhancement instead of 
heterogonous or diffuse enhancement of neoplastic tis-
sue [15].
In our study, there was 1 case diagnosed as non-malig-
nant on plain MRI without spectroscopy and as malig-
nant on MRI with spectroscopy. Two cases were diag-
nosed as malignant on MRI without spectroscopy but as 
non-malignant on MRI with spectroscopy, as compared to 
histopathology.
Thus, a combination approach consisting of T2WI, DWI, 
ADC values, DCE-MRI, and spectroscopy can better diag-
nose, detect, and localize prostatic lesions.
Figure 7.  Ca Prostate with seminal vesicle involvement, bladder base invasion and bone metastases. (A) T2W axial images shows diffuse 
hypointense signal in both PZ and TZ. (B) T2W Axial image showing hypointense signal in left seminal vesicle( blue arrow) and polypoidal 
growth in the bladder base. (C) STIR axial image showing multiple focal areas of hyperintense signal in pelvic bones( head of femur – 
arrow and pubic symphysis). (D) T1FS post contrast sagittal image showing heterogeneous enhancement of prostate with involvement of 
the adjacent bladder base .
A B
C D
Conclusions
The present study was undertaken to determine the role of 
transrectal ultrasound (TRUS), magnetic resonance imag-
ing (MRI), and magnetic resonance spectroscopy (MRS) in 
the evaluation of prostatic pathologies, mainly prostate 
neoplasms. TRUS, MRI, and MRS scans were reviewed, the 
prostatic lesions were identified and characterized, and the 
results were correlated with histopathological findings.
Due to a high cost, limited availability, and prolonged scan-
ning time, MRI and MRS is currently not recommended as 
a first-line investigation for detecting prostate neoplasms. 
USG (trans-abdominal and transrectal ultrasonography) 
remains the first-line investigation due to its low cost, easy 
reproducibility, widespread availability, time effectiveness, 
and comparable efficacy. However, in patients with equivo-
cal findings on USG and a high clinical suspicion of neo-
plasm, MRI with spectroscopy is advised for more accurate 
tumor diagnosis and staging.
Lahoti A.M. et al. – Role of magnetic resonance imaging…
835
© Pol J Radiol, 2017; 82: 827-836
MRI with MRS is highly effective in the detection, diagno-
sis, localization, characterization, and staging of clinically 
significant prostate cancer and other prostatic lesions. It 
also has potential applications for tumor staging and can 
predict the aggressiveness of tumors. The combination of 
MRI+MRS has an improved diagnostic accuracy in com-
parison to MRI alone for the detection of prostate neo-
plasms. MRS, though time consuming, plays a very impor-
tant adjuvant role to MRI in the evaluation of prostatic 
pathologies and prostatic tumors, and it should be includ-
ed in routine MR imaging protocols to evaluate prostatic 
pathologies.
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